Some point extracted from today’s ann that should make the market (hopefully regardless diamond’s effect)) bit more confident:
1- Upon commencement of the Company’s pivotal trial of ATL1102 in Europe, Dr Price’s responsibilities will also include pharmacovigilance oversight, adverse event reporting and clinical safety monitoring
***announcing something like that in my view it looks agreement with EMA for 2b is given for granted.***
2- Following the recently reported positive clinical trial results in the Phase II clinical trial of ATL1102, the Company is actively exploring clinical development opportunities where inflammation plays a key role in disease progression.
ATL1102 was previously shown to be highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients.
***also here management sound due to results sound very confident to explore applications ***
Now we need the much waited announcement referring DMD final report/results...
- Forums
- ASX - By Stock
- Ann: Quarterly Update and Appendix 4C
Some point extracted from today’s ann that should make the...
-
-
- There are more pages in this discussion • 37 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.9¢ |
Change
-0.002(2.47%) |
Mkt cap ! $81.90M |
Open | High | Low | Value | Volume |
8.0¢ | 8.1¢ | 7.8¢ | $1.034M | 12.98M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 7.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.0¢ | 305419 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 349999 | 0.079 |
13 | 925066 | 0.078 |
11 | 938445 | 0.077 |
6 | 776200 | 0.076 |
12 | 1232581 | 0.075 |
Price($) | Vol. | No. |
---|---|---|
0.080 | 305419 | 1 |
0.081 | 550144 | 3 |
0.082 | 599880 | 3 |
0.084 | 400000 | 1 |
0.085 | 40000 | 1 |
Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |